SNS

Sensei Biotherapeutics is a clinical-stage immuno-oncology company focused on discovering and developing next-generation therapeutics for cancer. The company utilizes its proprietary TMAb (Tumor Microenvironment Activated Biologics) platform to create conditionally active antibodies that selectively target immune checkpoints within the low-pH tumor microenvironment, minimizing off-tumor toxicities. Its lead program, solnerstotug (SNS-101), is a pH-selective antibody targeting the VISTA checkpoint, currently being evaluated in Phase 1/2 trials for solid tumors. In early 2026, the company expanded its pipeline through the acquisition of Faeth Therapeutics and its lead candidate Piktor, while securing significant private placement financing to support its clinical objectives.